Catalyst Pharmaceutical Partners and BioMarin Pharmaceutical Enter Into Strategic Collaboration for Firdapse(TM) in North

Catalyst Pharmaceutical Partners and BioMarin Pharmaceutical Enter Into
Strategic Collaboration for Firdapse(TM) in North America

     BioMarin to Make $5 Million Strategic Equity Investment in Catalyst

Catalyst Licenses North American Rights to Firdapse™, a Phase III Orphan Drug
        for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)

   Catalyst Expects Top-Line CPP-109 Phase II(b) Data During First Half of
                                   November

CORAL GABLES, Fla., Oct. 31, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX) and BioMarin Pharmaceutical Inc. (Nasdaq:BMRN)
today announced that they have entered into a strategic collaboration for the
rights to Firdapse™ in North America. Firdapse™ is an orphan product, which
has been approved in the European Union (EU) and is undergoing a Phase III
clinical trial in the United States, for the treatment of Lambert-Eaton
Myasthenic Syndrome (LEMS), a rare, debilitating and sometimes fatal
autoimmune disease with the primary symptoms of muscle weakness. The key
components of the collaboration include Catalyst licensing the exclusive North
American rights to Firdapse™ and BioMarin making a $5 million investment in
Catalyst to rapidly advance the Firdapse™ program in the United States.

Patrick J. McEnany, Catalyst's Chief Executive Officer, stated: "As part of
this arrangement, we are gaining access to a late-stage U.S. orphan drug
targeting LEMS, a disease of the central nervous system for which there is not
currently an effective treatment approved in the United States. Our existing
product candidates are focused on addiction and central nervous system orphan
indications like Infantile Spasms/West Syndrome and Tourette's Disorder, and
adding Firdapse™ is consistent with our product development strategy. The
relationship with BioMarin is exciting and strategically important, as it
provides Catalyst with another orphan drug candidate and near-term funding
towards the completion of the currently underway Phase III trial for
Firdapse™."

Under the terms of the collaboration, Catalyst and BioMarin have entered into
a:

  *Convertible Promissory Note and Note Purchase Agreement under which
    BioMarin has invested $5 million in Catalyst, which will convert on a
    mandatory basis into Catalyst common stock at a future date. The
    conversion price will be based on the dollar weighted average of
    Catalyst's common stock during the 15 business day period prior to the
    conversion date. Catalyst has covenanted to BioMarin that the $5 million
    investment will be used solely for the purpose of developing Firdapse™ in
    the United States.
    
  *License Agreement in which Catalyst receives the exclusive rights to
    Firdapse™ for all indications in North America. Catalyst will be
    responsible for all future costs of developing and commercializing
    Firdapse™ in North America, and will share equally the cost of various
    post-marketing studies in the EU, the data from which is also anticipated
    to be included in the Firdapse™ registration package in the United States.
    Subject to certain criteria, Catalyst will also owe royalty payments to
    BioMarin, and milestone and royalty payments to the former shareholders of
    Huxley Pharmaceuticals and to a third-party licensor of the rights being
    sublicensed to Catalyst.

Mr. McEnany continued: "Additionally, as previously announced, we are
continuing to communicate closely with the Department of Veterans Affairs
Cooperative Studies Program (VACSP), the collaborator responsible for the
management, verification and statistical analyses of the data being collected
in our Phase II(b) trial for the treatment of cocaine addiction. Based on
information received to date, we continue to expect that we will receive and
be in a position to report the top-line results from our trial during the
first half of November 2012."

About Firdapse™

Firdapse™, also known as amifampridine phosphate, 3,4-diaminopyridine or
3,4-DAP, is a potassium channel blocker. It delays repolarization of the
pre-synaptic neuron, causing voltage gated Ca2+ channels to remain open
longer. The increased Ca2+ influx causes more acetylcholine to be released,
making it more likely that a muscle action potential will be initiated,
thereby reducing muscle weakness. BioMarin acquired the rights to Firdapse™ as
part of its acquisition of Huxley Pharmaceuticals in 2009. Since then,
BioMarin has commercialized Firdapse™ in the EU for LEMS, where it has orphan
medicinal product designation.

In the United States, where it also has orphan drug designation, Firdapse™ is
in a Phase III, multicenter, double-blind, placebo-controlled, randomized
discontinuation study followed by an open-label extension period to evaluate
the efficacy and safety of Firdapse™ in patients with LEMS. Upon completion of
this transaction, Catalyst will be responsible for the overall management and
continuing this already initiated study. The estimated enrollment for the U.S.
Phase III study is 30 LEMS patients. In addition to LEMS, other potential
orphan central nervous system indications for Firdapse™ include Myasthenia
Gravis and Congenital Myasthenic Syndrome, among others.

About United States Orphan Drug Designation

Orphan drug designation is granted by the U.S. Food & Drug Administration
(FDA) Office of Orphan Drug Products to promote the development of drugs and
biologics for the treatment of rare diseases and disorders that affect fewer
than 200,000 persons in the United States. The key benefit includes a 7-year
period of market exclusivity if Firdapse™ is the first of its type approved
for the specified indication or if it demonstrates superior safety, efficacy
or a major contribution to patient care versus another drug of its type
previously granted the designation for the same indication. Other potential
benefits include tax credits for certain clinical research costs, annual grant
funding, clinical trial design assistance and waiver of Prescription Drug User
Fee Act (PDUFA) filing fees.

About LEMS

Lambert-Eaton Myasthenic Syndrome is a rare autoimmune disease with the
primary symptoms of muscle weakness. The muscle weakness in LEMS is caused by
autoantibodies to voltage gated calcium channels leading to a reduction in the
amount of acetylcholine released from nerve terminals. The prevalence of LEMS
is estimated at approximately 3,000 patients in the United States and Canada.
Approximately 50 percent of LEMS patients diagnosed have small cell lung
cancer. Patients with LEMS typically present with fatigue, muscle pain and
stiffness. The weakness is generally more marked in the proximal muscles,
particularly of the legs and trunk. Other problems include reduced reflexes,
drooping of the eyelids, facial weakness and problems with swallowing.
Patients often report dry mouth, impotence, constipation and feelings of light
headedness on standing. These problems can be life threatening when the
weakness involves respiratory muscles. A diagnosis of LEMS is generally made
on the basis of clinical symptoms, electromyographic testing and the presence
of autoantibodies against voltage gated calcium channels.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty
pharmaceutical company focused on the development and commercialization of
prescription drugs targeting diseases and disorders of the central nervous
system. Catalyst has two products in development and is currently evaluating
its lead product candidate, CPP-109 (vigabatrin, a GABA aminotransferase
inhibitor), for the treatment of cocaine addiction and Tourette's Disorder.
CPP-109 has been granted "Fast Track" status by the FDA for the treatment of
cocaine addiction. Catalyst also expects to evaluate CPP-109 for the treatment
of other addictions. Catalyst is also developing CPP-115, another GABA
aminotransferase inhibitor that is more potent than vigabatrin and has reduced
side effects (e.g., visual field defects, or VFDs) from those associated with
vigabatrin. Catalyst is planning to develop CPP-115 for several indications,
including drug addiction, epilepsy and for use in other selected central
nervous system indications. CPP-115 has been granted orphan drug designation
for the treatment of infantile spasms by the FDA and orphan medicinal product
designation by the European Commission. Catalyst believes that it controls all
current intellectual property for drugs that have a mechanism of action
related to the inhibition of GABA aminotransferase. For additional
information, please visit www.catalystpharma.com.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes innovative
biopharmaceuticals for serious diseases and medical conditions. Its product
portfolio comprises four approved products and multiple clinical and
pre-clinical product candidates. Approved products include Naglazyme®
(galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed
and commercialized by BioMarin; Aldurazyme® (laronidase) for
mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a
50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin
dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership
with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and
Firdapse™ (amifampridine), which has been approved by the European Commission
for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). Product
candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is
currently in Phase III clinical development for the treatment of MPS IVA,
amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in
Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL
(PEGylated recombinant phenylalanine ammonia lyase), which is currently in
Phase II clinical development for the treatment of PKU, BMN-701, a novel
fusion protein of insulin-like growth factor 2 and acid alpha glucosidase
(IGF2-GAA), which is currently in Phase I/II clinical development for the
treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase (PARP)
inhibitor, which is currently in Phase I/II clinical development for the
treatment of genetically-defined cancers, and BMN-111, a modified
C-nutriuretic peptide, which is currently in Phase I clinical development for
the treatment of achondroplasia. For additional information, please visit
www.bmrn.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties which may cause
actual results in future periods to differ materially from the statements made
herein. A number of factors, including whether Firdapse™ will be approved for
commercialization in the U.S., whether Catalyst will have sufficient resources
to complete the development of Firdapse™ in the U.S., whether Catalyst's
current Phase II(b) trial evaluating its product candidate CPP-109 for the
treatment of cocaine addiction will be successful, whether Catalyst's current
product candidates, CPP-109 and CPP-115, will ever be approved for
commercialization in the U.S., and those other factors described in Catalyst's
and BioMarin's filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect the forward-looking statements made in this release.
Copies of Catalyst's and BioMarin's filings with the SEC are available from
the SEC, may be found on the respective company's website or may be obtained
upon request from the respective company. Neither Catalyst nor BioMarin
undertake any obligation to update the information contained herein, which
speaks only as of this date.

CONTACT: Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
        
         Eugenia Shen
         BioMarin Pharmaceutical Inc.
         (415) 506-6570
        
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com